logo dark logo light logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
mobile-logo
  • 首页
  • 关于我们
    • 背景
    • 投资战略
    • 团队
  • 投资组合
  • 新闻中心
  • 联系我们
  • English
  • 投资者登录
 

新闻中心

31 5月 2019
by admin
in Uncategorized
Comments
Crescendo Biologics Announces Prestigious Academic Research Collaborations
28 5月 2019
by admin
in Uncategorized
Comments
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
24 5月 2019
by admin
in Uncategorized
Comments
Crescendo Biologics Achieves Another Milestone in its Strategic Collaboration with Takeda
19 5月 2019
by admin
in Uncategorized
Comments
Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals
16 5月 2019
by admin
in Uncategorized
Comments
TEMPEST THERAPEUTICS STARTS PHASE I/IB CLINICAL TRIAL WITH FIRST-IN-CLASS PPAR ALPHA ANTAGONIST
15 5月 2019
by admin
in Uncategorized
Comments
resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24

中国上海市浦东新区张江高科技园区金科路4560号金创大厦3号楼8楼,201210
电话: +86 21 6163 2598  |  传真: +86 21 6163 2570  |  邮件: info@quancapital.com

© Quan Capital. All rights reserved. Credit: Website Design